ArticleOncotarget2018
IgG4-related kidney disease: the effects of a Rituximab-based immunosuppressive therapy.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- IgG4-related disease with multiorgan involvement: a case-based review.Rheumatology international · 2021Pooled it
- Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders.Frontiers in immunology · 2019Pooled it
- Recurrent IgG4 Disease-Related Tubulointerstitial Nephritis Treated With Rituximab As Maintenance Therapy.Cureus · 2026Article
- IgG4-related kidney disease complicated with retroperitoneal fibrosis: A case report.World journal of clinical cases · 2023Article
- Progression to End-Stage Renal Disease Due to IgG4-Related Nephritis Refractory to Rituximab.Cureus · 2023Article
- Concurrent presentation of IgG4-related tubulointerstitial nephritis and ANCA MPO crescentic glomerulonephritis.Clinical nephrology. Case studies · 2022Article
- IgG4-related disease: Changing epidemiology and new thoughts on a multisystem disease.Journal of translational autoimmunity · 2021Review
- Renal Involvement in IgG4-Related Disease: From Sunlight to Twilight.Frontiers in medicine · 2021Article
- Long-term effects of intensive B cell depletion therapy in severe cases of IgG4-related disease with renal involvement.Immunologic research · 2020Article
- Long-term changes in renal function after treatment initiation and the importance of early diagnosis in maintaining renal function among IgG4-related tubulointerstitial nephritis patients in Japan.Arthritis research & therapy · 2020Article
- Low-density lipoprotein apheresis for PLA2R-related membranous glomerulonephritis accompanied by IgG4-related tubulointerstitial nephritis.CEN case reports · 2020Article
- Clinical features and outcomes in a cohort of patients with immunoglobulin G4-related disease at a university hospital in Spain.Clinical kidney journal · 2019Article
- A case report of IgG4-related disease: an insidious path to the diagnosis through kidney, heart and brain.BMC nephrology · 2019Article
- Clinical Manifestations and Long-term Outcomes of IgG4-Related Kidney and Retroperitoneal Involvement in a United Kingdom IgG4-Related Disease Cohort.Kidney international reports · 2019Article
- Eosinophilia and Kidney Disease: More than Just an Incidental Finding?Journal of clinical medicine · 2018Review
- Anti-Neurofascin-Associated Nephrotic-Range Proteinuria in Chronic Inflammatory Demyelinating Polyneuropathy.Kidney medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgG4-related disease (IgG4-RD) is a recently recognized disorder, characterized by elevated serum IgG4 concentrations, dense tissue infiltration of IgG4-positive plasma cells and storiform fibrosis. Treatment is usually based on steroids, however, relapses and long-term adverse effects are frequent. We prospectively studied 5 consecutive patients with histologically-proven IgG4-RD and renal involvement, treated with an extended Rituximab protocol combined with steroids. Two doses of intravenous cyclophosphamide were added in 4 patients. Five patients with IgG-RD were investigated: three had tubulointerstitial nephritis (TIN), while two had retroperitoneal fibrosis (RPF). In the patients with TIN, renal biospy was repeated after 1 year. In the patients with TIN, estimated glomerular filtration rate (eGFR) at 12 months increased from 9 to 24 ml/min per 1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.